ArticleBMC medical informatics and decision making2025
Attention-driven hybrid deep learning and SVM model for early Alzheimer's diagnosis using neuroimaging fusion.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Explainable Patient-Level Cognitive Impairment Screening via Temporal, Semantic, and Psycholinguistic Multimodal AI.Journal of Intelligence · 2026Article
- MRI neuroimaging-based Alzheimer's disease stage classification using deep neural network with convolutional block attention module and GAN-style noise injection.Scientific reports · 2026Article
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Designing implicit population learners: a permutation-equivariant state space approach for brain disease diagnosis.Frontiers in computational neuroscience · 2026Article
- Effective deep convolutional neural network with attention mechanism for Alzheimer disease classification.Frontiers in radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) poses a significant global health challenge, necessitating early and accurate diagnosis to enable timely interventions. AD is a progressive neurodegenerative disorder that affects millions worldwide and is one of the leading causes of cognitive impairment in older adults. Early diagnosis is critical for enabling effective treatment strategies, slowing disease progression, and improving the quality of life for patients. Existing diagnostic methods often struggle with limited sensitivity, overfitting, and reduced reliability due to inadequate feature extraction, imbalanced datasets, and suboptimal model architectures. This study addresses these gaps by introducing an innovative methodology that combines SVM with Deep Learning (DL) to improve the classification performance of AD. Deep learning models extract high-level imaging features which are then concatenated with SVM kernels in a late-fusion ensemble. This hybrid design leverages deep representations for pattern recognition and SVM's robustness on small sample sets. This study provides a necessary tool for early-stage identification of possible cases, so enhancing the management and treatment options. This is attained by precisely classifying the disease from neuroimaging data. The approach integrates advanced data pre-processing, dynamic feature optimization, and attention-driven learning mechanisms to enhance interpretability and robustness. The research leverages a dataset of MRI and PET imaging, integrating novel fusion techniques to extract key biomarkers indicative of cognitive decline. Unlike prior approaches, this method effectively mitigates the challenges of data sparsity and dimensionality reduction while improving generalization across diverse datasets. Comparative analysis highlights a 15% improvement in accuracy, a 12% reduction in false positives, and a 10% increase in F1-score against state-of-the-art models such as HNC and MFNNC. The proposed method significantly outperforms existing techniques across metrics like accuracy, sensitivity, specificity, and computational efficiency, achieving an overall accuracy of 98.5%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.